Sun Pharma and the Technion form Research Collaboration to Develop New Class of Oncology Drugs
Sun Pharmaceutical Industries Ltd. and the Technion – Israel institute of technology announced that their respective subsidiaries have entered into an exclusive worldwide research and license agreement. This agreement aims at the development of a joint project, based on new findings by Nobel Prize laureate Distinguished Professor Aaron Ciechanover, Dr. Gila Maor and Professor Ofer Binah, that can potentially lead to the development of novel anti-cancer drugs. The pre-clinical research was funded thus far by Dr. Alfred Mann.
“We are very excited about this new endeavor between Sun Pharma, with the Technion. We are confident that this collaboration will help us move rapidly forward with our research” said Ciechanover and Binah. "We explored several collaboration alternatives, but Sun Pharma’s market leadership and its long term commitment have made this collaboration a very high priority for us".
"The Technion is delighted to partner with Sun Pharma to advance this project through pre-clinical development process. This collaboration is an excellent example of interactions between academic discovery and pharmaceutical companies demonstrating the valuable contribution academic institutions can make in bringing new products to help patients worldwide. We sincerely believe this agreement represents the beginning of a long and fruitful relationship between the Technion and Sun Pharma", added Ciechanover and Binah.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
